All In Biotech

Drug Trial Radar · NCT02431598

Eovist vs. Dotarem Healthy Volunteer MRI

Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact

Last checked: Nov 20, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Jun 2015

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, San Diego; University of Wisconsin, Madison
First posted
May 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold.

Conditions

  • Transient Severe Arterial Phase Motion

Interventions

  • gadoxetate disodiumDrug

  • gadoterate dimeglumineDrug

  • SalineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her BreathTime frame: following contrast administration, up to 5 minutes
  2. Subject-reported Dyspnea, as Measured by Questionnaire ResponsesTime frame: following contrast administration, up to 5 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.